{"version":"1.0","provider_name":"Malaysian Tribune","provider_url":"https:\/\/malaysiantribune.com","author_name":"admin","author_url":"https:\/\/malaysiantribune.com\/author\/admin\/","title":"Junshi Biosciences Announces Submission of a Marketing Authorization Application to the European Medicines Agency for Toripalimab - Malaysian Tribune","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"wklxIRUtqP\"><a href=\"https:\/\/malaysiantribune.com\/junshi-biosciences-announces-submission-of-a-marketing-authorization-application-to-the-european-medicines-agency-for-toripalimab\/\">Junshi Biosciences Announces Submission of a Marketing Authorization Application to the European Medicines Agency for Toripalimab<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/malaysiantribune.com\/junshi-biosciences-announces-submission-of-a-marketing-authorization-application-to-the-european-medicines-agency-for-toripalimab\/embed\/#?secret=wklxIRUtqP\" width=\"600\" height=\"338\" title=\"&#8220;Junshi Biosciences Announces Submission of a Marketing Authorization Application to the European Medicines Agency for Toripalimab&#8221; &#8212; Malaysian Tribune\" data-secret=\"wklxIRUtqP\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","description":"\u2013The MAA was submitted in the EU for toripalimab seeking indications for the 1st line treatment of NPC and the 1st line treatment of ESCC \u2014 The global commercialization plan for toripalimab has expanded from China to the US and now, the EU SHANGHAI, China, Nov. 15, 2022 (GLOBE NEWSWIRE) \u2014 Shanghai Junshi Biosciences Co., [\u2026]","thumbnail_url":"https:\/\/ci3.googleusercontent.com\/proxy\/y54r392wFoCBLpj1nuU6P3B4jN5luvAvkGO0ibX0otWXZAsMX2ABjhAMsiF91DXajESPEs7XWQYbw38gnBbsLU_2PRW5UbXEHIzQNFRqxICE6cj8XWtRRrOCyXfNae0t=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY5NjcyNiM1MjY0MzUzIzIxOTUzNzU="}